Home COVID-19 Topics

COVID-19

New and Noteworthy

Poll: Most Adults Do Not Expect to Get a COVID-19 Shot This Fall; Many Parents Confused About Recommendations for Children

As federal vaccine policy changes, this poll finds that most adults do not expect to get a COVID-19 vaccine this fall , and many parents are confused and uncertain about whether the vaccine is recommended for healthy children this year. About one in adults nationally say the changes to vaccine policy are making people safer, while more than a third say they are making people less safe.

Exploring misinformation about covid

COVID Vaccine Concerns

Narratives about an FDA memo claiming COVID-19 vaccines caused 10 pediatric deaths have evolved from focusing on the unverified claims to framing the announcement as evidence of a broader government “cover-up,” as some have characterized it as vindication for those previously “silenced” for raising vaccine safety concerns.

Changing COVID-19 Booster Policies

Misinformation about COVID-19 Vaccines

Vaccine Misinformation Spreads as Children Head Back to School

Debunked Study Undermines COVID-19 Vaccine Recommendations

Additional Resources

Global COVID-19 Tracker

This tracker provides the number of cases and deaths from novel coronavirus by country, the trend in case and death counts by country, and a global map of showing which countries have cases and deaths.

COVID-19 and Related State Data

Use this tool to create custom reports of COVID-19 and related state data. Group COVID-19 cases and deaths with indicators like total hospitalizations, vaccinations and mental illness.

Latest News

More KFF Health News

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

View the Latest: COVID-19

Filter

List Grid

71 - 80 of 778 Results

  • Premature Mortality During COVID-19 in the U.S. and Peer Countries

    Issue Brief

    This analysis finds that the U.S. had the highest rate of premature deaths amid the COVID-19 pandemic in 2020-2021 among a group of 12 large, wealthy peer countries. The U.S. on average had more than two times the average years of life lost per 100,000 people as the United Kingdom, the country with the next highest rate.

  • Racial Disparities in Premature Deaths During the COVID-19 Pandemic

    Issue Brief

    This analysis examines the impact of the COVID-19 pandemic by race and ethnicity through the lens of premature mortality, using the measures of premature mortality rate and years of life lost among excess deaths that occurred during the pandemic.

  • Analysis of National Trends in Medicaid and CHIP Enrollment During the COVID-19 Pandemic

    Issue Brief

    This data note looks at national and state-by-state Medicaid and CHIP enrollment data through December 2022. After declines in enrollment from 2017 through 2019, preliminary data for December 2022 show that total Medicaid/CHIP enrollment grew to 92.3 million, an increase of 21.2 million from enrollment in February 2020 (29.8%), right before the pandemic and when enrollment began to steadily increase (Figure 1).

  • KFF COVID-19 Vaccine Monitor: March 2023

    Poll Finding

    As the COVID-19 public health emergency comes to an end, about half of adults say they would be likely to get an annual COVID-19 booster. Around one in three adults don't think they have ever had COVID-19, nor have they ever tested positive for it, and they primarily attribute this to taking precautions such as avoiding crowds.

  • The Implications of COVID-19 for Mental Health and Substance Use

    Issue Brief

    This brief explores mental health and substance use during, and prior to, the COVID-19 pandemic. We highlight populations that were more likely to experience worse mental health and substance use outcomes during the pandemic and discuss some innovations in the delivery of services.

  • How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?

    Issue Brief

    This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.